BRIEF

on INTEGRAGEN (EPA:ALINT)

IntegraGen: Revenue up despite loss of SeqOIA

Stock price chart of INTEGRAGEN (EPA:ALINT) showing fluctuations.

IntegraGen announced a turnover of €4.5 million for the first half of 2024, recording a decrease of 20% compared to the same period in 2023. This decline results from the cessation of services for the SeqOIA platform, reducing revenue of €885k compared to €2.2m the previous year.

Excluding SeqOIA, other activities grew by 6%. Cash available at June 30, 2024 stood at €2.8 million, down by one million compared to the end of 2023. This decline is explained by variations in customer payment terms and the repayment of loans.

With a strengthened order book and obtaining CLIA certification, IntegraGen plans sustained growth. The Managing Director, Bernard Courtieu, highlights the efforts focused on high-margin activities and cost reduction measures to meet the current challenges.

R. H.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all INTEGRAGEN news